JIMENEZ

HIV-1 infection
Tenofovir is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-1 infected adults.
Tenofovir is also indicated for the treatment of HIV-1 infected adolescents, with NRTI resistance or toxicities precluding the use of first line agents, aged 12 to < 18 years. The choice of Tenofovir to treat antiretroviral-experienced patients with HIV-1 infection should be based on individual viral resistance testing and/or treatment history of patients. Hepatitis B infection Tenofovir is indicated for the treatment of chronic hepatitis B in adults with: • compensated liver disease, with evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis. • evidence of lamivudine-resistant hepatitis B virus. • decompensated liver disease Tenofovir are indicated for the treatment of chronic hepatitis B in adolescents 12 to < 18 years of age with: • compensated liver disease and evidence of immune active disease, i.e. active viral replication, persistently elevated serum ALT levels and histological evidence of active inflammation and/or fibrosis This is only the preview. Please check here for the full indication.

Anatomical Therapeutic Chemical: J
Dosage form: Film coated tablet
Packaging: 10's x 3
Therapeutic area: Active pharmaceutical ingredient: